Postprogression outcomes in patients with ovarian carcinoma associated with a mutation in a non-BRCA homologous recombination repair gene receiving rucaparib maintenance treatment: Results from the phase III study ARIEL3

Objective: In the ARIEL3 study (NCT01968213), rucaparib maintenance treatment significantly improved progression-free survival (PFS) versus placebo in all predefined, nested cohorts (BRCA mutant; BRCA mutant + wildtype BRCA/high loss of heterozygosity; and intent-to-treat population). Here we analyzed postprogression outcomes to evaluate the durability of the clinical benefit of rucaparib maintenance treatment following disease progression in...